Welcome!

Cognitive Computing Authors: Liz McMillan, Yeshim Deniz, Shelly Palmer, Elizabeth White, Rajeev Kozhikkattuthodi

News Feed Item

Global Regenerative Medicine Industry

NEW YORK, Dec. 11, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Regenerative Medicine Industry
http://www.reportlinker.com/p090567/Global-Regenerative-Medicine-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Blood_Supply,_Tissue_Banking_and_Transplantation

This report analyzes the worldwide markets for Regenerative Medicine in US$ million. The report provides separate comprehensive analytics for the US, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. A six-year historic analysis is also provided for these markets. The report profiles 93 companies including many key and niche players such as BioVest International, Inc., Curis, Inc., Cytori Therapeutics, Inc., Evotec AG, Forticell Bioscience, Inc., Geron Corporation, Integra LifeSciences Corporation, LifeCell Corporation, Osiris Therapeutics, Inc., Tengion, Inc., Tepha Inc., and TiGenix N.V. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.



I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-2
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3




II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW II-1
A Primer II-1
Current and Future Analysis II-1
Current Global Market for Regenerative Medicine II-2
Therapeutic Companies and Products in Regenerative Medicine -
Current Status II-2
Select Therapeutic Regenerative Medicine Products in the
Global Market II-3
Market Potential II-3



2. REGENERATIVE MEDICINE IN BONE AND JOINT APPLICATIONS II-5
An Overview of Regenerative Medicine in Bone and Joint
Applications II-5
Bone Graft Substitutes - Penetration in Foot and Ankle Surgeries II-5
Repair of Non-Healing Bones - High Market Potential II-5
Market Potential of Bone Graft Substitutes (BGSs) II-6
Table 1: Global Bone Graft Substitute Market (2010):
Percentage Share Breakdown of Sales for DePuy, OrthoVita,
ApaTech/Baxter, Wright Medical, Medtronic/RTI, Biomet, and
Others (includes corresponding Graph/Chart) II-6
Synthetic Bone Graft Substitutes to Replace Traditional
Autografts and Allografts II-6
Select Synthetic Products in Orthobiologics II-7
Bone Morphogenic Proteins (BMPs) Gaining Popularity II-7
Bone Morphogenic Protein products in Orthobiology II-7
Table 2: Global Bone Morphogenic Protein Market (2010):
Percentage Share Breakdown of Sales for Medtronic/RTI, and
Stryker (includes corresponding Graph/Chart) II-7
Demineralized Bone Matrices (DBMs) Market Getting Crowded II-8
Table 3: Global Demineralized Bone Matrix Market (2011):
Percentage Share Breakdown of Value Sales for Medtronic/RTI,
Synthes/MTF, Integra LifeSciences, Altiva, Bacterin, and
Others (includes corresponding Graph/Chart) II-8
Select DBM products in Orthobiologics market II-8
Biomaterials Market - Promising Opportunities for Cost-
Effective Products II-8
Existing Bone Graft Procedures - Limitations and Concerns II-9
Autograft Procedures II-9
Allograft - DBM and Other Allografts II-9
BMPs and Other Synthetic Growth Factors II-9
Medical Devices and Implants for Orthopedics II-10
Expanding Opportunities in Hip and Knee Market II-10
Extremity Reconstruction - A Growing Market II-10
Tissue Engineered Cartilage Market - An Overview II-11
Tissue Engineered Cartilages - A Promising Solution for
Cartilage Repair II-11
Market Potential of Tissue Engineered Cartilage Products II-11
Potential Applications of Tissue Engineered Cartilage Products II-11
Commercially Available tissue engineered cartilage products II-12
Challenges in Clinical Application of Tissue Engineered
Cartilage Products II-13
Bone Marrow Transplants (BMTs) II-13
Market Potential for BMTs II-14
Companies Engaged in CBSC Research for BMTs II-14
Table 4: Global Orthobiologics Market (2010): Percentage
Share Breakdown of Value Sales for Medtronic/RTI,
Synthes/MTF, DePuy, Osteotech, Orthofix, and Others
(includes corresponding Graph/Chart) II-14



Table 5: Global Orthobiologics Market (2010): Percentage
Share Breakdown of Value Sales by Product Type for Growth
Factors, Synthetics, DMBs, Allografts, and Stem Cells
(includes corresponding Graph/Chart) II-15



Table 6: Global Machined Bone and Allograft Market (2010):
Percentage Share Breakdown of Value Sales for Synthes/MTF,
DePuy, Medtronic/RTI, Osteotech, RTIX, and Others (includes
corresponding Graph/Chart) II-15



Table 7: Global Stem Cell Orthobiologics Market (2010):
Percentage Share Breakdown of Value Sales for Nuvasive, and
Otrhofix includes corresponding Graph/Chart) II-15



Table 8: Global Bone Growth Stimulation Market (2010):
Percentage Share Breakdown of Value Sales for Orthofix,
Biomet, DJO and Smith & Nephew (includes corresponding
Graph/Chart) II-16



Table 9: Global Spinal Stimulation Market (2010): Percentage
Share Breakdown of Value Sales for Orthofix, Biomet and DJO
(includes corresponding Graph/Chart) II-16



Table 10: Global Long Bone Stimulation Market (2010):
Percentage Share Breakdown of Value Sales for Smith& Nephew,
DJO, Biomet and Orthofix (includes corresponding
Graph/Chart) II-16
Regenerative Medicine in Other Areas II-16
Wound Healing - The Second Largest Segment II-16
Cardiology - Promising Opportunities II-17
Diabetes - Highly Effective Innovative Treatments II-17
Neurodegenerative Diseases - Great Potential II-17
Body Sculpting/Cosmetics - High Potential II-18
Table 11: Global Market for Regenerative Medicine in Body
Reconstruction and Cosmetics (2014): Value Sales by Target
Area (in US$ Million) (includes corresponding Graph/Chart) II-18
Regenerative Medicine - the Past, the Present, & the Future II-18
Another Revolution in the Making? II-20
Conventional Chemical Medicine Vs Regenerative Medicine II-20
Regenerative Medicine - The Need of Modern Era II-21
Regenerative Medicine Throws in Several New Therapies II-21
What's in Store? II-21
Regenerative Medicine to Arrest Ageing? II-21
Thriving on an Aging World Population II-22
Faster Healing Process II-22
Regenerative Medicine to Overcome Donor Organs Shortage II-23
Possible Scenarios II-23
Stem Cell Research - Not Just Another Medical Advancement II-23
Sources of Stem Cells II-24
Japanese Technology in the Area of Stem Cells II-24
Progenitor Cell Therapy to Witness No Holds Barred Growth II-25
Key Issues at Play II-25
Ethical Angle of Embryonic Stem Cell Research II-25
Growth Drivers for Regenerative Medicine II-26
A Combination of Factors to Drive Regenerative Medicine Market II-26
Aging Population Provides a Ready Market for Innovative
Therapies II-26
Scientific and Technological Advances in Associated Areas II-26
Government Support and Increased Private Sector Participation II-26
Investment and Funding Landscape II-27



3. TRENDS & ISSUES II-28
A Promising Outlook II-28
Increased Activity in the Field of Regenerative Medicine II-28
Recent Advancements in the Science of Regenerative Medicine II-28
Nanotechnology in Regenerative Medicine II-29
Advances in Nanotechnology Assist Regenerative Medicine II-29
Players Embrace Automation in Production Facilities II-30
Contract Manufacturing - A Growing Sector II-30
Issues to be Sorted Out II-30
Need for New Scientific and Technological Standards II-30
Standardized Guidelines II-31
Clinical Translation - Collaboration of Multidisciplinary
Skills is Essential II-31
The Question of Apt Business Models - The Service and
Product Approach II-32
Table 12: Percentage Breakdown of Autologous and Allogeneic
Approach by Therapeutic Firms Across Select Countries (2011)
(includes corresponding Graph/Chart) II-32
Autologous or Service Approach Preferred by European Firms II-33
Allogeneic or Product Approach - Slow to Develop II-33
Regenerative Medicine Requires Improved Biomaterials II-33
Assessment of Worldwide R&D Activities in the Area of
Biomaterials II-34
Investors Wary of Funding Regenerative Medicine II-34
Regenerative Medicine Field Lags Behind due to Segregated Focus II-35
Challenges Encountered by Regenerative Medicine II-35
Scientific and Technological Challenges II-35
Barriers in Sharing Intellectual Property Rights II-36
Viable Manufacturing Technologies and Skilled Personnel Crucial II-36
Strict Regulations Push up Operational Costs II-37
Scientific and Technological Challenges in Orthopedics II-37
Bone Regeneration II-37
Clinical Approaches in Bone Regeneration and Their Limitations II-37



4. PRODUCT OVERVIEW II-39
Regenerative Medicine Advances in Four Phases II-39
Human Substances II-39
Tissue Engineering II-39
Therapeutic Cloning II-39
Nanotechnology-Driven Biomaterials II-39
Types of Regenerative Medicine II-40
Type I - Regenerative Medicine II-40
Human Proteins and Genes are Drugs in Regenerative Medicine II-40
Type-2 Regenerative Medicine II-40
Therapies Based on Human Cells and Tissues II-40
Type-3 Regenerative Medicine II-42
Based on Embryonic Stem Cells II-42
The Opponents of the ESC Theory II-43
Embryonic Stem Cells - Shortcomings II-43
Type-4 Regenerative Medicine II-44
Based on Novel Materials / Material Science Advancements II-44
Overview of Major Regenerative Medicine Techniques II-45
Natural Regenerative Proteins II-45
Tissue Engineering Capable of Culturing Replacement Organs II-45
All About Stem Cells II-46
Adult Stem Cells II-46
Adult Stem Cell Research Eludes Ethical Dispute II-46
hESC - Highly Capable of Differentiating and Multiplying II-47
Stem Cell Research in Development of Regenerative Medicine II-47
Neural Stem Cell to Restore Memory Functioning II-47
Pancreatic Islet Cells to Control Blood Sugar in Diabetics II-48
Therapeutic Cloning to Cure Parkinson's II-48



5. REGULATORY ENVIRONMENT II-49
Global Regulatory Landscape II-49
US II-49
EU II-49
Japan II-49
Regulatory Norms Governing ES Cell Research II-50
Milestones in the Human Embryonic Stem Cell Research: 2001 II-50
Legality of ES Cell Use in Major Developed Nations II-50



6. TECHNOLOGICAL INNOVATIONS/ BREAKTHROUGHS II-51
BioMimetic Therapeutics to Launch Augmatrix™ Biocomposite
Bone Graft II-51
TEI Biosciences Introduces PriMatrix™ Ag Antimicrobial Dermal
Repair Scaffold II-51

7. TECHNOLOGICAL INNOVATIONS IN RECENT PAST A PERSPECTIVE BUILDER II-52
SANUWAVE Health Introduces orthoPACE™ in Europe II-52
Kensey Nash's Medeor ECM Receives Approval from US FDA II-52
Celling Technologies Unveils Res-Q Device II-52
Kinetic Wins FDA Approval for LifeCell Tissue Matrix II-53



8. RECENT INDUSTRY ACTIVITY II-54
BioMimetic Therapeutics Secures CE Mark Approval for GEM 21S®
in EU II-54
WFIRM and Nantong University Set-up China-US Regenerative and
Translational Medicine Research Center II-54
EMD Millipore Collaborates with Centre for Commercialization
of Regenerative Medicine II-54
American CryoStem Associates with Alliance for Regenerative
Medicine II-55
TAP Biosystems Collaborates with a leading Regenerative
Medicine Company II-55
Cytomedix Acquires Aldagen II-55
Centre for Commercialization of Regenerative Medicine Sets Up
Industry Consortium II-56
Tengion Conducts Preclinical Study for Small Intestine
Regeneration II-56
TiGenix Inks Agreement with Cellerix for Combining Business
Operations II-56
La Jolla Pharmaceutical Acquire Rights to Regenerative
Immunophilin Ligands from GliaMed II-57
Medtronic Acquires Minority Stake in Tengion II-57
ImageIQ to Enter into Partnership with CCBC, NCRM and
Cleveland Clinic II-58
Centre for Commercialization of Regenerative Medicine
Collaborates with McEwen Centre for Regenerative Medicine II-58
LifeNet Health Sets Up Institute of Regenerative Medicine II-59
UK Government Sets Out Plan for Regenerative Medicine II-59



9. CORPORATE ACTIVITY IN RECENT PAST - A PERSPECTIVE BUILDER II-60
Healthpoint Acquires Cell-based Technologies and Allied
Assets from Intercytex II-60
Astellas Pharma to Acquire Equity Stake in Cytori Therapeutics II-60
Cephalon Enters into Partnership with Mesoblast II-61
BioTime and California Institute for Regenerative Medicine
Ink Agreement II-61
The Automation Partnership Extends Partnership with EPSRC
Centre for Innovative Manufacturing in Regenerative Medicine II-61
The Alliance for Regenerative Medicine Introduces
Regenerative Medicine Promotion Act II-62
Power3 Medical Inks Definitive Agreement to Acquire StemTroniX II-62
Healthpoint Acquires CYZACT™ and ICX-SKN Technologies from
Intercytex II-62
Stem Cell Therapy International Merges with Histostem II-63
TiGenix Acquires Orthomimetics II-63
Integra Inks Licensing Deal with Organogenesis II-63
DePuy Spine Collaborates with ATRM II-63
Epistem Enters into Partnership with Novartis II-63
Athersys Inks Agreement with Pfizer II-64
Beike Biotechnology Signs Investment Agreement with Biomaster II-64
Fujifilm Establishes New Drug Discovery Labs II-64



10. FOCUS ON SELECT GLOBAL PLAYERS II-65
BioVest International, Inc. (US) II-65
Curis, Inc. (US) II-65
Cytori Therapeutics, Inc. (US) II-66
Evotec AG (Germany) II-67
Forticell Bioscience, Inc. (US) II-67
Geron Corporation (US) II-68
Integra LifeSciences Corporation (US) II-68
LifeCell Corporation (US) II-69
Osiris Therapeutics, Inc. (US) II-69
Tengion, Inc. (US) II-70
Tepha Inc. (US) II-70
TiGenix N.V. (Belgium) II-71



11. GLOBAL MARKET PERSPECTIVE II-73
Table 13: World Recent Past, Current & Future Market Analysis
for Regenerative Medicine Products for Bone and Joint
Applications by Geographic Region - US, Europe and Rest of
World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2010 through 2018 (includes
corresponding Graph/Chart) II-73



Table 14: World Historic Review for Regenerative Medicine
Products for Bone and Joint Applications by Geographic Region -
US, Europe and Rest of World Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2004
through 2009 (includes corresponding Graph/Chart) II-74



Table 15: World 15-Year Perspective for Regenerative Medicine
Products for Bone and Joint Applications by Geographic Region -
Percentage Breakdown of Dollar Sales for US, Europe and Rest
of World Markets for Years 2004, 2011 & 2018 (includes
corresponding Graph/Chart) II-75
Regenerative Medicine Market by Application II-76
Table 16: World Recent Past, Current & Future Market Analysis
for Regenerative Medicine Products for Bone and Joint
Applications by Application - Bone Replacements, Bone
Stimulators, and Tissue Replacements Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2010 through 2018 (includes corresponding Graph/Chart) II-76



Table 17: World Historic Review for Regenerative Medicine
Products for Bone and Joint Applications by Application - Bone
Replacements, Bone Stimulators, and Tissue Replacements
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2004 through 2009 (includes
corresponding Graph/Chart) II-77



Table 18: World 15-Year Perspective for Regenerative Medicine
Products for Bone and Joint Applications by Application -
Percentage Breakdown of Dollar Sales for Bone Replacements,
Bone Stimulators, and Tissue Replacements Markets for Years
2004, 2011 & 2018 (includes corresponding Graph/Chart) II-78




III. MARKET

1. THE UNITED STATES III-1
A.Market Analysis III-1
Current and Future Analysis III-1
US to Retain Leadership Position III-1
The Strength of US in Regenerative Medicine - A Glance III-1
Factors Driving the US Market of Regenerative Medicine III-2
Millions of American Patients Put their Hope in Stem Cell
Research III-2
Table 19: Prevalence of Various Diseases in the US
(includes corresponding Graph/Chart) III-3
High Potential for Regenerative Medicine in Orthopedics III-3
Regenerative Medicine in Bone and Joint Applications III-3
Regenerative Therapy - Best Fit for Joint Problems III-4
Table 20: US Market for Regenerative Medicine Products for
Bone and Joint Applications (2011, 2015 & 2018):
Percentage Breakdown of Value Sales for Bone Replacement
Grafting, Bone Growth Stimulators, and Tissue Engineering
Cartilage (includes corresponding Graph/Chart) III-5



Table 21: US Demineralized Bone Matrices Market (2011):
Percentage Share Breakdown of Value Sales for Leading
Players (includes corresponding Graph/Chart) III-5



Table 22: US Cartilage Procedure Market by Volume:
2012-2018 (in Million Procedures) (includes corresponding
Graph/Chart) III-6
Regenerative Medicine - Other Areas of Application III-6
Regenerative Medicine - Face of Future Revolution in
Cardiology III-6
Regenerative Medicine in Wound Healing - The Most
Widespread Application III-6
Regenerative Medicine in Diabetes - A Number of Emerging
Applications III-7
Regenerative Medicine - A Ray of Hope for
Neurodegenerative Disease Patients III-7
Major Scientific Breakthroughs and Developments in
Regenerative Medicine III-7
CBI's Human Tissue Products for Treating Liver Failure and
Diabetes III-8
Market for Liver and Pancreas Transplantation III-8
Implantable Regenerative Products Take Over Sports Medicine III-8
Challenges in the Area of Product Development III-9
Process of Integration Continues III-9
Legal Entangles in the Field of Regenerative Medicine -
Cause for Concern III-9
Scientific and Technological Challenges to be Tackled III-10
Dominant Patents a Cause of Concern III-10
Technological Innovations/Breakthroughs III-11
Strategic Corporate Developments III-12
Key Players III-13
B.Market Analytics III-21
Table 23: US Recent Past, Current & Future Analysis for
Regenerative Medicine Products for Bone and Joint
Applications Market with Annual Sales Figures in US$ Million
for Years 2010 through 2018 (includes corresponding
Graph/Chart) III-21



Table 24: US Historic Review for Regenerative Medicine
Products for Bone and Joint Applications Market with Annual
Sales Figures in US$ Million for Years 2004 through 2009
(includes corresponding Graph/Chart) III-22



2. EUROPE III-23
A.Market Analysis III-23
Current and Future Analysis III-23
Great Potential for Regenerative Medicine III-23
Challenges Faced by European Regenerative Medicine Industry III-23
Financial Viability - A Growing Concern in the Backdrop of
Euro Crisis III-24
The Need to Embrace Newer Technologies III-24
Complex Regulatory Scenario with Multi-tier Governance System III-24
Need for More Integration III-24
Policies Regarding Egg Procurement Weigh Down Research
Progress III-25
Need for Harmonized Clinical Trial Regulation III-25
International Alliances - Outsourcing Options with
Developing Countries III-26
Patenting Issues in hESC Research III-26
Oral Tissue Regeneration III-27
Table 25: European Oral Tissue Regeneration Market (2011):
Percentage Breakdown of Value Sales for Bone Graft
Material, Membranes, and Tissue Regeneration (includes
corresponding Graph/Chart) III-27
Overview of select regional markets III-27
Germany III-27
United Kingdom III-27
UK Government Sets Out Plan for Regenerative Medicine III-28
Barriers to Commercialization III-28
Strategic Corporate Developments III-28
Key players III-30
B.Market Analytics III-31
Table 26: European Recent Past, Current & Future Analysis
for Regenerative Medicine Products for Bone and Joint
Applications Market with Annual Sales Figures in US$
Million for Years 2010 through 2018 (includes corresponding
Graph/Chart) III-31



Table 27: European Historic Review for Regenerative Medicine
Products for Bone and Joint Applications Market with Annual
Sales Figures in US$ Million for Years 2004 through 2009
(includes corresponding Graph/Chart) III-32



3. REST OF WORLD III-33
A.Market Analysis III-33
Current and Future Analysis III-33
Canada III-33
A Significant Player in the Field of Regenerative Medicine III-33
Regulatory and Legislative Scenario III-33
University of Toronto - Spearheading Regenerative Medicine
Research III-34
Asia-Pacific III-34
Japan III-34
Growth Drivers III-34
Regenerative Medicine Market for Bone and Joint Applications III-35
The Expanding RM market for Cartilage Grafts III-35
Regenerative Bone Grafts - Slow Progress of Research a
Concern III-35
Other Areas in Regenerative Medicine III-35
Skin Transplantation III-35
Pancreas & Liver Transplantation III-35
Research Activity in Regenerative Medicine Field III-35
More Companies Eye the Regenerative Medicine Potential III-36
Competition Heats up Behind Closed Doors III-36
Japanese Firms Need to Catch Up with US and European
Competitors III-37
Science Ministry Rolls Out Regenerative Medicine Project III-37
Regenerative Medicine Exempted from Ban on Human Cloning III-37
Issues and Concerns III-38
Regulatory Issues - Need for Faster Approvals III-38
Need for Participation in International Standardization III-39
China III-39
Substantial Government Support III-39
India III-39
CSIR- Leading the way in Regenerative Medicine Research III-39
High Growth Opportunities III-39
South Korea III-40
Malaysia III-40
Singapore III-40
Latin America III-41
Argentina III-41
Brazil III-41
Highly Promising but Challenges Remain III-41
Inconsistent Government Funding Poses Hurdles for Long-
Term Research III-42
Import Costs and Delays - An Impediment for the RM Sector III-42
Underestimation of Brazilian Innovation - A Concern III-42
Greater Integration Needed the Need of the Hour III-43
Lack of Interest in IP Protection Results in Lesser Patents III-43
Africa III-43
South Africa III-43
Strategic Corporate Developments III-44
Key players III-45
B.Market Analytics III-46
Table 28: Rest of World Recent Past, Current & Future
Analysis for Regenerative Medicine Products for Bone and
Joint Applications Market with Annual Sales Figures in US$
Million for Years 2010 through 2018 (includes corresponding
Graph/Chart) III-46



Table 29: Rest of World Historic Review for Regenerative
Medicine Products for Bone and Joint Applications Market
with Annual Sales Figures in US$ Million for Years 2004
through 2009 (includes corresponding Graph/Chart) III-47




IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 93 (including Divisions/Subsidiaries - (98)

The United States (53)
Canada (1)
Japan (12)
Europe (18)
- Germany (5)
- The United Kingdom (7)
- Rest of Europe (6)
Asia-Pacific (Excluding Japan) (10)
Latin America (1)
Africa (1)
Middle East (2)



To order this report:
Blood_Supply,_Tissue_Banking_and_Transplantation Industry:
Global Regenerative Medicine Industry

__________________________
Contact Nicolas: [email protected]
US: (805)-652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

@ThingsExpo Stories
Join IBM November 1 at 21st Cloud Expo at the Santa Clara Convention Center in Santa Clara, CA, and learn how IBM Watson can bring cognitive services and AI to intelligent, unmanned systems. Cognitive analysis impacts today’s systems with unparalleled ability that were previously available only to manned, back-end operations. Thanks to cloud processing, IBM Watson can bring cognitive services and AI to intelligent, unmanned systems. Imagine a robot vacuum that becomes your personal assistant tha...
In his Opening Keynote at 21st Cloud Expo, John Considine, General Manager of IBM Cloud Infrastructure, will lead you through the exciting evolution of the cloud. He'll look at this major disruption from the perspective of technology, business models, and what this means for enterprises of all sizes. John Considine is General Manager of Cloud Infrastructure Services at IBM. In that role he is responsible for leading IBM’s public cloud infrastructure including strategy, development, and offering ...
In a recent survey, Sumo Logic surveyed 1,500 customers who employ cloud services such as Amazon Web Services (AWS), Microsoft Azure, and Google Cloud Platform (GCP). According to the survey, a quarter of the respondents have already deployed Docker containers and nearly as many (23 percent) are employing the AWS Lambda serverless computing framework. It’s clear: serverless is here to stay. The adoption does come with some needed changes, within both application development and operations. Tha...
SYS-CON Events announced today that Avere Systems, a leading provider of enterprise storage for the hybrid cloud, will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Avere delivers a more modern architectural approach to storage that doesn't require the overprovisioning of storage capacity to achieve performance, overspending on expensive storage media for inactive data or the overbui...
Widespread fragmentation is stalling the growth of the IIoT and making it difficult for partners to work together. The number of software platforms, apps, hardware and connectivity standards is creating paralysis among businesses that are afraid of being locked into a solution. EdgeX Foundry is unifying the community around a common IoT edge framework and an ecosystem of interoperable components.
SYS-CON Events announced today that TidalScale will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. TidalScale is the leading provider of Software-Defined Servers that bring flexibility to modern data centers by right-sizing servers on the fly to fit any data set or workload. TidalScale’s award-winning inverse hypervisor technology combines multiple commodity servers (including their ass...
SYS-CON Events announced today that N3N will exhibit at SYS-CON's @ThingsExpo, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. N3N’s solutions increase the effectiveness of operations and control centers, increase the value of IoT investments, and facilitate real-time operational decision making. N3N enables operations teams with a four dimensional digital “big board” that consolidates real-time live video feeds alongside IoT sensor data a...
As hybrid cloud becomes the de-facto standard mode of operation for most enterprises, new challenges arise on how to efficiently and economically share data across environments. In his session at 21st Cloud Expo, Dr. Allon Cohen, VP of Product at Elastifile, will explore new techniques and best practices that help enterprise IT benefit from the advantages of hybrid cloud environments by enabling data availability for both legacy enterprise and cloud-native mission critical applications. By rev...
With major technology companies and startups seriously embracing Cloud strategies, now is the perfect time to attend 21st Cloud Expo October 31 - November 2, 2017, at the Santa Clara Convention Center, CA, and June 12-14, 2018, at the Javits Center in New York City, NY, and learn what is going on, contribute to the discussions, and ensure that your enterprise is on the right path to Digital Transformation.
Join IBM November 1 at 21st Cloud Expo at the Santa Clara Convention Center in Santa Clara, CA, and learn how IBM Watson can bring cognitive services and AI to intelligent, unmanned systems. Cognitive analysis impacts today’s systems with unparalleled ability that were previously available only to manned, back-end operations. Thanks to cloud processing, IBM Watson can bring cognitive services and AI to intelligent, unmanned systems. Imagine a robot vacuum that becomes your personal assistant th...
Digital transformation is changing the face of business. The IDC predicts that enterprises will commit to a massive new scale of digital transformation, to stake out leadership positions in the "digital transformation economy." Accordingly, attendees at the upcoming Cloud Expo | @ThingsExpo at the Santa Clara Convention Center in Santa Clara, CA, Oct 31-Nov 2, will find fresh new content in a new track called Enterprise Cloud & Digital Transformation.
Most technology leaders, contemporary and from the hardware era, are reshaping their businesses to do software. They hope to capture value from emerging technologies such as IoT, SDN, and AI. Ultimately, irrespective of the vertical, it is about deriving value from independent software applications participating in an ecosystem as one comprehensive solution. In his session at @ThingsExpo, Kausik Sridhar, founder and CTO of Pulzze Systems, will discuss how given the magnitude of today's applicati...
Smart cities have the potential to change our lives at so many levels for citizens: less pollution, reduced parking obstacles, better health, education and more energy savings. Real-time data streaming and the Internet of Things (IoT) possess the power to turn this vision into a reality. However, most organizations today are building their data infrastructure to focus solely on addressing immediate business needs vs. a platform capable of quickly adapting emerging technologies to address future ...
SYS-CON Events announced today that Ryobi Systems will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Ryobi Systems Co., Ltd., as an information service company, specialized in business support for local governments and medical industry. We are challenging to achive the precision farming with AI. For more information, visit http:...
As popularity of the smart home is growing and continues to go mainstream, technological factors play a greater role. The IoT protocol houses the interoperability battery consumption, security, and configuration of a smart home device, and it can be difficult for companies to choose the right kind for their product. For both DIY and professionally installed smart homes, developers need to consider each of these elements for their product to be successful in the market and current smart homes.
SYS-CON Events announced today that Golden Gate University will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Since 1901, non-profit Golden Gate University (GGU) has been helping adults achieve their professional goals by providing high quality, practice-based undergraduate and graduate educational programs in law, taxation, business and related professions. Many of its courses are taug...
What is the best strategy for selecting the right offshore company for your business? In his session at 21st Cloud Expo, Alan Winters, U.S. Head of Business Development at MobiDev, will discuss the things to look for - positive and negative - in evaluating your options. He will also discuss how to maximize productivity with your offshore developers. Before you start your search, clearly understand your business needs and how that impacts software choices.
SYS-CON Events announced today that Avere Systems, a leading provider of hybrid cloud enablement solutions, will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Avere Systems was created by file systems experts determined to reinvent storage by changing the way enterprises thought about and bought storage resources. With decades of experience behind the company’s founders, Avere got its ...
High-velocity engineering teams are applying not only continuous delivery processes, but also lessons in experimentation from established leaders like Amazon, Netflix, and Facebook. These companies have made experimentation a foundation for their release processes, allowing them to try out major feature releases and redesigns within smaller groups before making them broadly available. In his session at 21st Cloud Expo, Brian Lucas, Senior Staff Engineer at Optimizely, will discuss how by using...
In this strange new world where more and more power is drawn from business technology, companies are effectively straddling two paths on the road to innovation and transformation into digital enterprises. The first path is the heritage trail – with “legacy” technology forming the background. Here, extant technologies are transformed by core IT teams to provide more API-driven approaches. Legacy systems can restrict companies that are transitioning into digital enterprises. To truly become a lead...